Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Esophagus
Erschienen in: Esophagus 1/2021

Open Access 13.10.2020 | Special Article

Comprehensive registry of esophageal cancer in Japan, 2013

verfasst von: Masayuki Watanabe, Yuji Tachimori, Tsuneo Oyama, Yasushi Toh, Hisahiro Matsubara, Masaki Ueno, Koji Kono, Takashi Uno, Ryu Ishihara, Kei Muro, Hodaka Numasaki, Koji Tanaka, Soji Ozawa, Kentaro Murakami, Shiyori Usune, Arata Takahashi, Hiroaki Miyata, The Registration Committee for Esophageal Cancer of the Japan Esophageal Society

Erschienen in: Esophagus | Ausgabe 1/2021

insite
INHALT
download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Background

Esophageal cancer is the eighth most common cause of cancer mortality in Japan. More than 11,000 people had died from esophageal cancer in 2018. The Japan Esophageal Society has collected the data on patients' characteristics, performed treatment, and outcomes annually.

Methods

We analyzed the data of patients who had first visited the participating hospitals in 2013. In 2019, the data collection method was changed from an electronic submission to a web-based data collection using the National Clinical Database (NCD). Japanese Classification of Esophageal Cancer 10th by the Japan Esophageal Society (JES) and UICC TNM Classification 7th were used for cancer staging

Results

A total of 8019 cases were registered from 334 institutions in Japan. Squamous cell carcinoma and adenocarcinoma accounted for 87.8% and 6.3%, respectively. The 5-year survival rates of patients treated using endoscopic resection, concurrent chemoradiotherapy, radiotherapy alone, or esophagectomy were 88.3%, 32.4%, 24.4%, and 59.3%, respectively. Esophagectomy was performed in 4910 cases. The operative and the hospital mortality rates were 0.77% and 1.98%, respectively. The survival curves showed a good discriminatory ability both in the clinical and pathologic stages by the JES system. The 5-year survival rate of patients with pStage IV in the UICC classification that included patients with supraclavicular node metastasis was better than that of patients with pStage IVb in JES classification.

Conclusion

We hope this report contributes to improving all aspects of the diagnosis and treatment of esophageal cancer in Japan.
Hinweise
These data were first made available on July 15, 2020, as the Comprehensive Registry of Esophageal Cancer in Japan, 2013.
The authors were members of the Registration Committee for Esophageal Cancer, the Japan Esophageal Society, and made great contribution to the preparation of this material.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Preface 2013

We deeply appreciate the great contributions of many physicians in the registry of esophageal cancer cases. The Comprehensive Registry of Esophageal Cancer in Japan, 2013, was published here. In 2019, the data collection method was changed from an electronic submission to a web-based data collection using the National Clinical Database (NCD). Personal information was replaced with individual management code inside each institute, and the NCD collected only anonymized information. The registry complies with the Act for the Protection of Personal Information.
We briefly summarized the Comprehensive Registry of Esophageal Cancer in Japan, 2013. Japanese Classification of Esophageal Cancer 10th by the Japan Esophageal Society (JES) [1] and UICC TNM Classification 7th [2] were used for cancer staging according to the subjected year. A total of 8019 cases were registered from 334 institutions in Japan. Tumor locations were cervical: 4.8%, upper thoracic: 12.1%, middle thoracic: 46.5%, lower thoracic: 28.2% and EG junction: 7.9%. Superficial carcinomas (Tis, T1a, T1b) were 38.6%. As for the histologic type of biopsy specimens, squamous cell carcinoma and adenocarcinoma accounted for 87.8% and 6.3%, respectively. Regarding clinical results, the 5-year survival rates of patients treated using endoscopic resection, concurrent chemoradiotherapy, radiotherapy alone, or esophagectomy were 88.3%, 32.4%, 24.4%, and 59.3%, respectively. The endoscopic submucosal dissection accounted for 91.6% of endoscopic resection. Esophagectomy was performed in 4910 cases. Concerning the approach used for esophagectomy, 43.0% of the cases were treated thoracoscopically. The operative mortality (within 30 days after surgery) was 0.77%, and the hospital mortality was 1.98%. The Kaplan–Meier survival curves diverged according to the N-grade both in the JES and the UICC classifications. The survival curves showed a good discriminatory ability both in the clinical and pathologic stages by the JES system. However, the survival of cStage IIB was better than those of IB and IIA, while the survival curves were almost identical between cStage IIIc and IV in the UICC system. Also, the survival curve of pStage IIA merged with that of IIB, and the survival of pStage IV was better than that of IIIC. The 5-year survival rate of patients with pStage IV in the UICC classification that included patients with supraclavicular node metastasis was better than that of patients with pStage IVb in JES classification.
We hope that this Comprehensive Registry of Esophageal Cancer in Japan for 2013 will help to improve all aspects of the diagnosis and treatment of esophageal cancer in Japan.

Contents

I.
Clinical factors of esophageal cancer patients treated in 2013
1.
Institution-registered cases in 2013
 
2.
Patient background
  • Table 1 Age and gender
  • Table 2 Primary treatment
  • Table 3 Tumor location
  • Table 4 Histologic types of biopsy specimens
  • Table 5 Depth of tumor invasion, cT (UICC TNM 7th)
  • Table 6 Lymph node metastasis, cN (UICC TNM 7th)
  • Table 7 Distant metastasis, cM (UICC TNM 7th)
  • Table 8 Clinical stage (UICC TNM 7th)
 
 
II.
Results of endoscopically treated patients in 2013
  • Table 9 Details of endoscopic treatment for curative intent
  • Table 10 Complications of EMR/ESD
  • Table 11 Pathological depth of tumor invasion of EMR/ESD specimens
  • Figure 1 Survival of patients treated with EMR/ESD
  • Figure 2 Survival of patients treated with EMR/ESD according to the pathological depth of tumor invasion, pT (JES 10th)
  • Figure 3 Survival of patients treated with EMR/ESD according to the lymphatic and venous invasion
 
III.
Results in patients treated with chemotherapy and/or radiotherapy in 2013
  • Table 12 Dose of irradiation (non-surgically treated cases)
  • Table 13 Dose of irradiation (surgically treated cases)
  • Figure 4 Survival of patients treated with chemotherapy and/or radiotherapy
  • Figure 5 Survival of patients treated with definitive chemoradiotherapy according to clinical stage (UICC TNM 7th)
  • Figure 6 Survival of patients underwent radiotherapy alone according to clinical stage (UICC TNM 7th)
 
IV.
Results in patients who underwent esophagectomy in 2013
  • Table 14 Treatment modalities of esophagectomy
  • Table 15 Tumor location
  • Table 16 Approaches to tumor resection
  • Table 17 Video-assisted surgery
  • Table 18 Fields of lymph node dissection according to the location of the tumor
  • Table 19 Reconstruction route
  • Table 20 Organs used for reconstruction
  • Table 21 Histological classification
  • Table 22 Depth of tumor invasion, pT (JES 10th)
  • Table 23 Pathological grading of lymph node metastasis, pN (JES 10th)
  • Table 24 Pathological findings of lymph node metastasis, pN (UICC TNM 7th)
  • Table 25 Pathological findings of distant organ metastasis, pM (JES 10th)
  • Table 26 Residual tumor
  • Table 27 Causes of death
  • Figure 7 Survival of patients who underwent esophagectomy
  • Figure 8 Survival of patients who underwent esophagectomy according to clinical stage (JES 10th)
  • Figure 9 Survival of patients who underwent esophagectomy according to clinical stage (UICC TNM 7th)
  • Figure 10 Survival of patients who underwent esophagectomy according to the depth of tumor invasion, pT (JES 10th)
  • Figure 11 Survival of patients who underwent esophagectomy according to lymph node metastasis (JES 10th)
  • Figure 12 Survival of patients who underwent esophagectomy according to lymph node metastasis (UICC TNM 7th)
  • Figure 13 Survival of patients who underwent esophagectomy according to pathological stage (JES 10th)
  • Figure 14 Survival of patients who underwent esophagectomy according to pathological stage (UICC TNM 7th)
  • Figure 15 Survival of patients who underwent esophagectomy according to residual tumor (R)
 

I. Clinical features of esophageal cancer patients treated in 2013

Institution-registered cases in 2013.
Institutions
Ageo Central General Hospital
Aichi Cancer Center
Aichi Medical University Hospital
Aizawa Hospital
Akita University Hospital
Aomori Prefectural Central Hospital
Arao Municipal Hospital
Asahikawa Medical University Hospital
Cancer Institute Hospital of JFCR
Chiba Cancer Center
Chiba University Hospital
Chibaken Saiseikai Narashino Hospital
Chiba-Nishi General Hospital
Chigasaki Municipal Hospital
Chugoku Rosai Hospital
Dokkyo Medical University Hospital
Ehime Prefectural Central Hospital
Eijyu General Hospital
Fuchinobe General Hospital
Fuchu Hospital
Fujinomiya City General Hospital
Fujioka General Hospital
Fujisaki Hospital
Fujita Health University Hospital
Fukaya Red Cross Hospital
Fukui Prefectural Hospital
Fukui University Hospital
Fukui-ken Saiseikai Hospital
Fukuoka City Hospital
Fukuoka Shin Mizumaki Hospital
Fukuoka University Chikushi Hospital
Fukuoka University Hospital
Fukuoka Wajiro Hospital
Fukushima Medical University Hospital
Fukuyama City Hospital
Gifu Prefectural General Center
Gifu University Hospital
Gunma Prefectural Cancer Center
Gunma Saiseikai Maebashi Hospital
Gunma University Hospital
Hachinohe City Hospital
Hakodate City Hospital
Hakodate Goryokaku Hospital
Hakodate National Hospital
Hamamatsu University Hospital
Heartlife Hospital
Higashiosaka City Medical Center
Hiraka General Hospital
Hiratsuka City Hospital
Hiratsuka Kyosai Hospital
Hirosaki University Hospital
Hiroshima City Asa Hospital
Hiroshima City Hospital
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
Hiroshima University Hospital
Hitachi General Hospital
Hofu Institute of Gastroenterology
Hokkaido University Hospital
Hospital of the University of Occupational and Environmental Health, Japan
Hyogo Cancer Center
Hyogo Prefectural Amagasaki General Medical Center
Ibaraki Prefectural Central Hospital
Iizuka Hospital
International Goodwill Hospital
International University of Health and Welfare Atami Hospital
International University of Health and Welfare Hospital
International University of Health and Welfare Ichikawa Hospital
International University of Health and Welfare Mita Hospital
Isehara Kyodo Hospital
Ishikawa Prefectural Central Hospital
Itami City Hospital
Iwata City Hospital
Iwate Medical University Hospital
Iwate Prefectural Central Hospital
Iwate Prefectural Chubu Hospital
JA Hiroshima General Hospital
JA Kouseiren Enshu Hospital
JA Onomichi General Hospital
Japanese Red Cross Ashikaga Hospital
Japanese Red Cross Fukuoka Hospital
Japanese Red Cross Ishinomaki Hospital
Japanese Red Cross Kitami Hospital
Japanese Red Cross Kyoto Daiichi Hospital
Japanese Red Cross Maebashi Hospital
Japanese Red Cross Medical Center
Japanese Red Cross Musashino Hospital
Japanese Red Cross Nagasaki Genbaku Hospital
Japanese Red Cross Nagoya Daiichi Hospital
Japanese Red Cross Saitama Hospital
Japanese Red Cross Society Nagano Hospital
Japanese Red Cross Tottori Hospital
Japanese Red Cross Wakayama Medical Center
JCHO Gunma Chuo Hospital
JCHO Kyushu Hospital
JCHO Miyazaki Konan Hospital
JCHO Osaka Hospital
JCHO Saitama Medical Center
JCHO Tokuyama Central Hospital
JCHO Yokohama Chuo Hospital
Jichi Medical University Hospital
Jichi Medical University Saitama Medical Center
Juntendo University Hospital
Juntendo University Shizuoka Hospital
Juntendo University Urayasu Hospital
Junwakai Memorial Hospital
Kagawa Prefectural Central Hospital
Kagawa Rosai Hospital
Kagawa University Hospital
Kagoshima University Hospital
Kaizuka City Hospital
Kakogawa Central City hospital
Kanagawa Cancer Center
Kanazawa Medical University Hospital
Kanazawa University Hospital
Kansai Denryoku Hospital
Kansai Medical University Hospital
Kansai Medical University Medical Center
Kansai Rosai Hospital
Kanto Central Hospital
Kashiwa Kousei General Hospital
Kasugai Municipal Hospital
Kawasaki Hospital
Kawasaki Medical School Hospital
Kawasaki Medical School Kawasaki Hospital
Kawasaki Municipal Hospital
Kawasaki Municipal Ida Hospital
Kawasaki Saiwai Hospital
Keio University Hospital
Keiyukai Sapporo Hospital
Kindai University Hospital
Kindai University Nara Hospital
Kinki Central Hospital
Kiryu Kousei General Hospital
Kitaakita Municipal Hospital
Kitaharima Medical Center
Kitakyushu General Hospital
Kitakyushu Municipal Medical Center
Kitano Hospital
Kitasato University Hospital
Kobe City Medical Center General Hospital
Kobe University Hospital
Kochi Health Science Center
Kochi University Hospital
Kokura Memorial Hospital
Kouseiren Takaoka Hospital
Kumagai General Hospital
Kumamoto University Hospital
Kummoto Regional Medical Center
Kurashiki Central Hospital
Kurume University Hospital
Kyorin University Hospital
Kyoto University Hospital
Kyoto-Katsura Hospital
Kyushu Central Hospital
Kyushu University Hospital
Machida Municipal hospital
Matsudo City General Hospital
Matsushita Memorial Hospital
Matsuyama Red Cross Hospital
Mie University Hospital
Minamiosaka Hospital
Minoh City Hospital
Mito Red Cross Hospital
Mitsui Memorial Hospital
Miyazaki University Hospital
Mizushima Kyudo Hospital
Moriguchi Keijinkai Hospital
Murakami General Hospital
Nagahama City Hospital
Nagahama Red Cross Hospital
Nagano Municipal Hospital
Nagaoka Chuo General Hospital
Nagasaki University Hospital
Nagoya City University Hospital
Nagoya City West Medical Center
Nagoya University Hospital
Nanpuh Hospital
Nara City Hospital
Nara Medical University Hospital
Nasu Red Cross Hospital
National Cancer Center Hospital
National Cancer Center Hospital East
National Center for Global Health and Medicine
National Defence Medical College Hospital
New Tokyo Hospital
NHO Beppu Medical Center
NHO Chiba Medical Center
NHO Fukuoka-Higashi Medical Center
NHO Iwakuni Clinincal Center
NHO Kanmon Medical Center
NHO Kure Medical Center
NHO Kyoto Medical Center
NHO Kyushu Cancer Center
NHO Matsumoto Medical Center
NHO Mito Medical Center
NHO Miyakonojo Medical Center
NHO Nagasaki Medical Center
NHO Nagoya Medical Center
NHO Okayama Medical Center
NHO Osaka Medical Center
NHO Saitama Hospital
NHO Sendai Medical Center
NHO Shikoku Cancer Center
NHO Tokyo Medical Center
NHO Yokohama Medical Center
Nihonkai General Hospital
Niigata Cancer Center Hospital
Niigata City General Hospital
Niigata Prefectural Central Hospital
Niigata Prefectural Shibata Hospital
Niigata University Medical & Detal Hospital
Nikko Memorial Hospital
Nippon Medical School Chiba Hokusou Hospital
Nippon Medical School Hospital
Nippon Medical School Musashi Kosugi Hospital
Nippon Medical School Tama Nagayama Hospital
Nishi Kobe Medical Center
Nissan Tamagawa Hospital
Nozaki Tokushukai Hospital
Numazu City Hospital
Obihiro Kousei Hospital
Ogaki Municipal Hospital
Ohta Hospital
Ohta Nishinouchi Hospital
Oita Red Cross Hospital
Oita University Hospital
Okayama Red Cross General Hospital
Okayama Saiseikai General Hospital
Okayama University Hospital
Okitama Public General Hospital
Onomichi Municipal Hospital
Osaka City General Hospital
Osaka City University Hospital
Osaka Ekisaikai Hospital
Osaka General Medical Center
Osaka International Cancer Institute
Osaka Medical College Hospital
Osaka Police Hospital
Osaka Red Cross Hospital
Osaki City Hospital
Otsu City Hospital
Rinku General Medical Center
Saga Prefectural Hospital Koseikan
Saga University Hospital
Sagamihara National Hospital
Saiseikai Fukuoka General Hospital
Saiseikai Karatsu Hospital
Saiseikai Noe Hospital
Saiseikai Utsunomiya Hospital
Saiseikai Yokohama Tobu Hospital
Saitama Cancer Center
Saitama Medical University International Medical Center
Saitama Medical University Saitama Medical Center
Sakai City Medical Center
Saku Central Hospital
Sapporo Medical University Hospital
Seikei-kai Chiba Medical Center
Sendai City Hospital
Shiga General Hospital
Shiga University of Medical Science Hospital
Shimane University Hospital
Shin Takeo Hospital
Shinko Hospital
Shinshu University Hospital
Shizuoka Cancer Center
Shizuoka City Shizuoka Hospital
Shizuoka General Hospital
Shizuoka Saiseikai General Hospital
Showa University Hospital
Southern Tohoku General Hospital
St. Luke's International Hospital
St. Marianna University School of Medicine Hospital
St. Mary's Hospital
Steel Memorial Yawata Hospital
Suita Municipal Hospital
Suzuka Chuo General Hospital
Tachikawa Hospital
Takatsuki Red Cross Hospital
Teikyo University Chiba Medical Center
Teikyo University Hospital
Teine Keijinkai Hospital
Tenri Hospital
The Hospital of Hyogo College of Medicine
The Jikei University Daisan Hospital
The Jikei University Hospital
Tochigi Cancer Center
Toho University Ohashi Medical Center
Toho University Omori Medical Center
Toho University Sakura Medical Center
Tohoku University Hospital
Tokai University Hachioji Hospital
Tokai University Hospital
Tokai University Tokyo Hospital
Tokushima Red Cross Hospital
Tokushima University Hospital
Tokyo Dental College Ichikawa General Hospital
Tokyo Medical and Dental University Hospital
Tokyo Medical University Hachioji Medical Center
Tokyo Medical University Hospital
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Tokyo Metropolitan Tama Medical Center
Tokyo Rosai Hospital
Tokyo University Hospital
Tokyo Women's Medical University Hospital
Tokyo Women's Medical University Medical Center East
Tokyo Women's Medical University Yachiyo Medical Center
Tonan Hospital
Toranomon Hospital
Tosei General Hospital
Toshima Hospital
Tottori Prefectural Central Hospital
Tottori University Hospital
Toyama Prefectural Central Hospital
Toyama University Hospital
Toyonaka Municipal Hospital
Toyota Memorial Hospital
Tsuchiura Kyodo Hospital
Tsukuba University Hospital
Tsuruoka Municipal Shonal Hospital
Tsuyama Chuo Hospital
University Hospital Kyoto Prefectural University of Medicine
University of the Ryukyus Hospital
Wakayama Medical University Hospital
Yamagata Prefectural Central Hospital
Yamagata University Hospital
Yamaguchi University Hospital
Yamanashi Prefectural Central Hospital
Yamanashi University Hospital
Yao Municipal Hospital
Yokohama City Municipal Hospital
Yokohama City University Hospital
Yokohama City University Medical Center
Yokohama Sakae Kyosai Hospital
Yokosuka General Hospital Uwamachi
(Total 334 institutions)

Patient background

Tables 1, 2, 3, 4, 5, 6, 7, 8
Table 1
Age and gender
Age
Male
Female
Cases (%)
 ≤ 29
12
1
13 (0.2%)
30–39
16
6
22 (0.3%)
40–49
164
59
223 (2.8%)
50–59
917
174
1091 (13.6%)
60–69
2675
431
3106 (38.7%)
70–79
2403
437
2840 (35.4%)
80–89
570
133
703 (8.8%)
90 ≤ 
10
11
21 (0.3%)
Total
6767
1252
8019
Table 2
Performed treatment
Treatments
Cases (%)
Surgery
5038 (62.8%)
 Esophagectomy
4910 (61.2%)
 Palliative surgery
128 (1.6%)
Chemotherapy and/or Radiotherapy
4062 (50.7%)
Endoscopic treatment
1421 (17.7%)
Table 3
Tumor location
Location of tumor
Endoscopic treatment
Surgery
Chemotherapy and/or radiotherapy (%)
Total (%)
(%)
Esophagectomy (%)
Palliative surgery (%)
Cervical
48 (3.4%)
163 (3.3%)
10 (7.8%)
256 (6.3%)
384 (4.8%)
Upper thoracic
142 (10.0%)
525 (10.7%)
25 (19.5%)
597 (14.7%)
969 (12.1%)
Middle thoracic
775 (54.5%)
2188 (44.6%)
61 (47.7%)
1864 (45.9%)
3726 (46.5%)
Lower thoracic
369 (26.0%)
1544 (31.4%)
26 (20.3%)
1118 (27.5%)
2264 (28.2%)
EG
61 (4.3%)
356 (7.3%)
5 (3.9%)
165 (4.1%)
470 (5.9%)
E = G
14 (1.0%)
66 (1.3%)
 
23 (0.6%)
88 (1.1%)
GE
6 (0.4%)
61 (1.2%)
 
15 (0.4%)
72 (0.9%)
Unknown
6 (0.4%)
7 (0.1%)
1 (0.8%)
45 (0.6%)
46 (0.6%)
Total
1421
4910
128
4062
8019
E esophageal, G gastric
Table 4
Histologic type of biopsy specimens
Histologic types
Endoscopic treatment
Surgery
Chemotherapy and/or radiotherapy (%)
Total (%)
(%)
Esophagectomy (%)
Palliative surgery (%)
Squamous cell carcinoma
1101 (77.5%)
4291 (87.4%)
116 (90.6%)
3733 (91.9%)
6911 (86.2%)
 Squamous cell carcinoma
867 (61.0%)
2442 (49.7%)
74 (57.8%)
2330 (57.4%)
4377 (54.6%)
 Well differentiated
100 (7.0%)
387 (7.9%)
9 (7.0%)
259 (6.4%)
565 (7.0%)
 Moderately differentiated
117 (8.2%)
1093 (22.3%)
24 (18.8%)
805 (19.8%)
1448 (18.1%)
 Poorly differentiated
17 (1.2%)
369 (7.5%)
9 (7.0%)
339 (8.3%)
521 (6.5%)
Adenocarcinoma
38 (2.7%)
340 (6.9%)
4 (3.1%)
133 (3.3%)
419 (5.2%)
Barrett's carcinoma
33 (2.3%)
91 (1.9%)
1 (0.8%)
25 (0.6%)
133 (1.7%)
Adenosquamous carcinoma
2 (0.1%)
11 (0.2%)
 
4 (0.1%)
14 (0.2%)
Mucoepidermoid carcinoma
 
1 (0.0%)
  
1 (0.0%)
Basaloid carcinoma
2 (0.1%)
31 (0.6%)
 
16 (0.4%)
39 (0.5%)
Neuroendocrine tumor
 
1 (0.0%)
 
1 (0.0%)
2 (0.0%)
Neuroendocrine carcinoma
4 (0.3%)
21 (0.4%)
 
27 (0.7%)
34 (0.4%)
Undifferentiated carcinoma
 
6 (0.1%)
 
4 (0.1%)
9 (0.1%)
Malignant melanoma
 
15 (0.3%)
 
6 (0.1%)
19 (0.2%)
Carcinosarcoma
 
16 (0.3%)
1 (0.8%)
8 (0.2%)
19 (0.2%)
GIST
 
1 (0.0%)
  
1 (0.0%)
Adenoid cystic carcinoma
 
1 (0.0%)
  
1 (0.0%)
Nonepithelial tumors
2 (0.1%)
   
3 (0.0%)
Other epithelial tumors
17 (1.2%)
4 (0.1%)
 
8 (0.2%)
27 (0.3%)
Other tumors
51 (3.6%)
16 (0.3%)
 
13 (0.3%)
79 (1.0%)
Unknown
171 (12.0%)
64 (1.3%)
6 (4.7%)
84 (2.1%)
308 (3.8%)
Total
1421
4910
128
4062
8019
Table 5
Depth of tumor invasion, cT (UICC TNM 7th)
Clinical T
Endoscopic treatment
Surgery
Chemotherapy and/or radiotherapy (%)
Total (%)
(%)
Esophagectomy (%)
Palliative surgery (%)
cTX
12 (0.8%)
11 (0.2%)
1 (0.8%)
34 (0.8%)
80 (1.0%)
cT0
6 (0.6%)
4 (0.1%)
 
3 (0.1%)
14 (0.2%)
cT1a
1139 (80.2%)
247 (5.0%)
 
102 (2.5%)
1426 (17.8%)
cT1b
196 (13.8%)
1319 (26.9%)
9 (7.0%)
515 (12.7%)
1658 (20.7%)
cT2
4 (0.3%)
832 (16.9%)
4 (3.1%)
609 (15.0%)
1006 (12.5%)
cT3
41 (2.9%)
2223 (45.3%)
49 (38.3%)
2036 (50.1%)
2895 (36.1%)
cT4a
4 (0.3%)
133 (2.7%)
17 (13.3%)
257 (6.3%)
341 (4.3%)
cT4b
19 (1.3%)
141 (2.9%)
48 (37.5%)
506 (12.5%)
599 (7.5%)
Total
1421
4910
128
4062
8019
Table 6
Lymph node metastasis, cN (UICC TNM 7th)
Clinical N
Endoscopic treatment
Surgery
Chemotherapy and/or radiotherapy (%)
Total (%)
(%)
Esophagectomy (%)
Palliative surgery (%)
cN0
1351 (95.1%)
2278 (46.4%)
31 (24.2%)
1117 (27.5%)
4047 (50.5%)
cN1
38 (2.7%)
1704 (34.7%)
37 (28.9%)
1663 (40.9%)
2318 (28.9%)
cN2
22 (1.5%)
800 (16.3%)
43 (33.6%)
1009 (24.8%)
1301 (16.2%)
cN3
10 (0.7%)
128 (2.6%)
17 (13.3%)
273 (6.7%)
353 (4.4%)
Total
1421
4910
128
4062
8019
Table 7
Distant metastasis, cM (UICC TNM 7th)
Clinical M
Endoscopic treatment
Surgery
Chemotherapy and/or radiotherapy (%)
Total (%)
(%)
Esophagectomy (%)
Palliative surgery (%)
cM0
1406 (98.9%)
4753 (96.8%)
103 (80.5%)
3513 (86.5%)
7350 (91.7%)
cM1
15 (1.1%)
157 (3.2%)
25 (19.5%)
549 (13.5%)
669 (8.3%)
Total
1421
4910
128
4062
8019
Table 8
Clinical Stage (UICC TNM 7th)
Clinical stage
Endoscopic treatment
Surgery
Chemotherapy and/or radiotherapy (%)
Total (%)
(%)
Esophagectomy (%)
Palliative surgery (%)
Stage IA
1317 (92.7%)
1268 (25.8%)
7 (5.5%)
388 (9.6%)
2712 (33.8%)
Stage IB
3 (0.2%)
417 (8.5%)
3 (2.3%)
252 (6.2%)
492 (6.1%)
Stage IIA
8 (0.6%)
523 (10.7%)
10 (7.8%)
356 (8.8%)
629 (7.8%)
Stage IIB
15 (1.1%)
522 (10.6%)
 
389 (9.6%)
609 (7.6%)
Stage IIIA
19 (1.3%)
1169 (23.8%)
14 (10.9%)
952 (23.4%)
1375 (17.1%)
Stage IIIB
9 (0.6%)
514 (10.5%)
14 (10.9%)
488 (12.0%)
642 (8.0%)
Stage IIIC
17 (1.2%)
325 (6.6%)
55 (43.0%)
667 (16.4%)
821 (10.2%)
Stage IV
15 (1.1%)
157 (3.2%)
25 (19.5%)
549 (13.5%)
669 (8.3%)
Unknown
18 (1.3%)
15 (0.3%)
 
21 (0.5%)
70 (0.9%)
Total
1421
4910
128
4062
8019

II. Results of endoscopically treated patients in 2013

Tables 9, 10, 11, and Figs. 1, 2, 3.
Table 9
Details of endoscopic treatment for curative intent
Treatment details
Cases (%)
EMR
108 (8.0%)
EMR + YAG laser
1 (0.1%)
EMR + MCT/RFA
 
 ESD
1224 (90.2%)
 ESD + EMR
4 (0.3%)
ESD + PDT
 
 ESD + YAG laser
5 (0.4%)
 PDT
2 (0.1%)
 YAG laser
13 (1.0%)
Total
1357
EMR endoscopic mucosal resection, PDT photodynamic therapy, YAG yttrium aluminum garnet, MCT microwave coagulation therapy, ESD endoscopic submucosal dissection
Table 10
Complications of EMR/ESD
Complications of EMR/ESD
Cases (%)
None
1298 (92.7%)
Perforation
10 (0.7%)
Bleeding
1 (0.1%)
Mediastinitis
1 (0.1%)
Stenosis
23 (1.7%)
Others
 
Unknown
2 (0.1%)
Total
1335
Table 11
Pathologic depth of tumor invasion of MER/ESD specimens
Pathological depth of tumor invasion (pT)
Cases (%)
pTX
22 (1.6%)
pT0
7 (0.5%)
pT1a
1111 (82.8%)
pT1b
201 (15.0%)
pT2
 
pT3
1 (0.1%)
Total
1342

III. Results in patients treated with chemotherapy and/or radiotherapy in 2013

Tables 12, 13 and Figs. 4, 5, 6.
Table 12
Dose of irradiation (non-surgically treated cases)
Dose of irradiation (Gy)
Definitive
Palliative (%)
Recurrence (%)
Others (%)
Total (%)
Radiation alone (%)
With chemotherapy (%)
–29
2 (1.5%)
20 (2.4%)
23 (11.7%)
2 (5.9%)
1 (10.0%)
48 (4.0%)
30–39
4 (3.0%)
16 (1.9%)
33 (16.8%)
1 (2.9%)
2 (20.0%)
56 (4.7%)
40–49
7 (5.3%)
33 (4.0%)
40 (20.4%)
1 (2.9%)
3 (30.0%)
84 (7.0%)
50–59
15 (11.4%)
233 (28.2%)
35 (17.9%)
10 (29.4%)
2 (20.0%)
295 (24.6%)
60–69
98 (74.2%)
505 (61.1%)
63 (32.1%)
19 (55.9%)
2 (20.0%)
687 (57.3%)
70–
6 (4.5%)
18 (2.2%)
1 (0.5%)
1 (2.9%)
 
26 (2.2%)
Unknown
 
2 (0.2%)
1 (0.5%)
  
3 (0.3%)
Total
132
827
196
34
10
1199
Median (min–max)
60.0 (5.4–80.0)
60.0 (2.0–99.0)
50.0 (2.0–70.0)
60.0 (11.0–70.0)
43.2 (26.0–66.0)
60.0 (2.0–99.0)
Table 13
Dose of irradiation (surgically treated cases)
Dose of irradiation (Gy)
Preoperative irradiation (%)
Postoperative irradiation (%)
–29
4 (1.4%)
6 (10.0%)
30–39
62 (22.2%)
3 (5.0%)
40–49
177 (63.4%)
5 (8.3%)
50–59
19 (6.8%)
19 (31.7%)
60–69
10 (3.6%)
24 (40.0%)
70–
4 (1.4%)
2 (3.3%)
Unknown
3 (1.1%)
1 (1.7%)
Total
279
60
Median (min–max)
40.0 (2.0–99.0)
55.0 (16.0–75.9)

IV. Results in patients who underwent esophagectomy in 2013

Tables 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, and Figs. 7, 8, 9, 10, 11, 12, 13, 14, 15
Table 14
Treatment modalities of esophagectomy
Treatment modalities
Cases (%)
Esophagectomy alone
2336 (47.6%)
Esophagectomy + postoperative chemotherapy
385 (7.8%)
Esophagectomy + postoperative chemoradiotherapy
109 (2.2%)
Esophagectomy + postoperative radiotherapy
34 (0.7%)
Preoperative chemotherapy + esophagectomy
1558 (31.7%)
Preoperative chemoradiotherapy + esophagectomy
286 (5.8%)
Definitive radiotherapy + esophagectomy
6 (0.1%)
Definitive chemoradiotherapy + esophagectomy
101 (2.1%)
Others
95 (1.9%)
Total
4910
Table 15
Tumor location
Locations
Cases (%)
Cervical
166 (3.4%)
Upper thoracic
536 (10.9%)
Middle thoracic
2165 (44.1%)
Lower thoracic
1507 (30.7%)
EG
368 (7.5%)
E = G
85 (1.7%)
GE
72 (1.5%)
Unknown
11 (0.2%)
Total
4910
Table 16
Approaches to tumor resection
Approaches
Cases (%)
Cervical
135 (2.7%)
Right thoracic
4171 (84.9%)
Left thoracic
63 (1.3%)
Left thoracoabdominal
115 (2.3%)
Abdominal
171 (3.5%)
Transhiatal lower esophagectomy
94 (1.9%)
Transhiatal thoracic esophagectomy
100 (2.0%)
Sternotomy
2 (0.0%)
Others
46 (0.9%)
Unknown
13 (0.3%)
Total
4910
Thoracic includes thoracotomy and thoracoscopic
Abdominal includes laparotomy and laparoscopic
Table 17
Video-assisted surgery
Video-assisted surgery
Cases (%)
None
2444 (49.8%)
Thoracoscopy
1072 (21.8%)
Thoracoscopy + laparoscopy
1037 (21.1%)
Thoracoscopy + laparoscopy + mediastinoscopy
5 (0.1%)
Thoracoscopy + laparoscopy + other
 
Thoracoscopy + mediastinoscopy
 
Thoracoscopy + other
1 (0.0%)
Laparoscopy
237 (4.8%)
Laparoscopy + mediastinoscopy
11 (0.2%)
Laparoscopy + mediastinoscopy + other
11 (0.3%)
Mediastinoscopy
57 (1.2%)
Laparoscopy + other
2 (0.0%)
Others
30 (0.6%)
Unknown
3 (0.1%)
Total
4910
Table 18
Fields of lymph node dissection according to the location of tumor
Field of lymphadenectomy
Cervical
Upper thoracic
Middle thoracic
Lower thoracic
Abdominal
E = G
GE
Unknown
Total
None
5 (3.0%)
15 (2.8%)
24 (1.1%)
31 (2.1%)
6 (1.6%)
2 (2.4%)
2 (2.8%)
3 (27.3%)
88 (1.8%)
C
36 (21.7%)
8 (1.5%)
16 (0.7%)
10 (0.7%)
    
70 (1.4%)
C + UM
21 (12.7%)
1 (0.2%)
1 (0.0%)
4 (0.3%)
   
1 (9.1%)
28 (0.6%)
C + UM + MLM
10 (6.0%)
14 (2.6%)
47 (2.2%)
15 (1.0%)
1 (0.3%)
   
87 (1.8%)
C + UM + MLM + A
69 (41.6%)
336 (62.7%)
1098 (50.7%)
532 (35.3%)
62 (16.8%)
10 (11.8%)
1 (1.4%)
5 (45.5%)
2113 (43.0%)
C + UM + A
5 (3.0%)
4 (0.7%)
17 (0.8%)
7 (0.5%)
1 (0.3%)
 
1
 
35 (0.7%)
C + MLM
   
1 (0.1%)
    
1 (0.0%)
C + MLM + A
3 (1.8%)
6 (1.1%)
14 (0.6%)
9 (0.6%)
1 (0.3%)
   
33 (0.7%)
C + A
3 (1.8%)
3 (0.6%)
4 (0.2%)
6 (0.4%)
  
1 (1.4%)
 
17 (0.3%)
UM
1 (0.6%)
2 (0.4%)
9 (0.4%)
1 (0.1%)
1 (0.3%)
   
14 (0.3%)
UM + MLM
3 (1.8%)
8 (1.5%)
41 (1.9%)
24 (1.6%)
5 (1.4%)
1 (1.2%)
  
82 (1.7%)
UM + MLM + A
3 (1.8%)
124 (23.1%)
792 (36.6%)
668 (44.3%)
116 (31.5%)
16 (18.8%)
10 (13.9%)
 
1729 (35.2%)
UM + A
 
2 (0.4%)
12 (0.6%
9 (0.6%)
2 (0.5%)
   
25 (0.5%)
MLM
 
3 (0.6%)
8 (0.4%)
8 (0.5%)
4 (1.1%)
1 1.2%)
2 (2.8%)
 
26 (0.5%)
MLM + A
3 (1.8%)
4 (0.7%)
62 (2.9%)
154 (10.2%)
141 (38.3%)
43 (50.6%)
39 (54.2%)
 
446 (9.1%)
A
4 (2.4%)
6 (1.1%)
20 (0.9%)
28 (1.9%)
28 (7.6%)
12 (14.1%)
16 (22.0%)
2 (18.2%)
116 (2.4%)
Total
166
536
2165
1507
368
85
72
11
4910
C bilateral cervical nodes, UM upper mediastinal nodes, MLM middle-lower mediastinal nodes, A abdominal nodes
Table 19
Reconstruction route
Route
Cases (%)
None
62 (1.3%)
Subcutaneous
353 (7.2%)
Retrosternal
1971 (40.1%)
Posterior mediastinal
1972 (40.2%)
Intrathoracic
462 (9.4%)
Cervical
49 (1.0%)
Others
26 (0.5%)
Unknown
15 (0.3%)
Total
4910
Table 20
Organs used for reconstruction
Organs
Cases (%)
None
88 (1.3%)
Whole stomach
215 (4.3%)
Gastric tube
4114 (83.1%)
Jejunum
249 (5.0%)
Free jejunum
85 (1.7%)
Colon
162 (3.3%)
Free colon
8 (0.2%)
Others
32 (0.6%)
Total organs
4953
Total cases
4822
Table 21
Histological classification
Histological classification
Cases (%)
Squamous cell carcinoma
4086 (83.2%)
 Squamous cell carcinoma
756 (15.4%)
 Well differentiated
750 (15.3%)
 Moderately differentiated
1989 (40.5%)
 Poorly differentiated
591 (12.0%)
Adenocarcinoma
306 (6.2%)
Barrett's carcinoma
118 (2.4%)
Adenosquamous carcinoma
22 (0.4%)
Mucoepidermoid carcinoma
1 (0.0%)
Basaloid carcinoma
86 (1.8%)
Neuroendocrine tumor
1 (0.0%)
Neuroendocrine carcinoma
32 (0.7%)
Undifferentiated carcinoma
8 (0.2%)
Malignant melanoma
16 (0.3%)
Carcinosarcoma
43 (0.9%)
GIST
2 (0.0%)
Adenoid cystic carcinoma
3 (0.1%)
Sarcoma
2 (0.0%)
Other carcinomas
3 (0.1%)
Other tumors
41 (0.8%)
Unknown
140 (2.9%)
Total
4910
Table 22
Pathological depthe of tumor invasion, pT (JES 10th)
Pathological depth of tumor invasion
Cases (%)
pTx
72 (1.5%)
pT0
161 (3.3%)
pT1a
589 (12.0%)
pT1b
1339 (27.3%)
pT2
607 (12.4%)
pT3
1898 (38.7%)
pT4a
138 (0.8%)
pT4b
106 (2.2%)
Total
4910
Table 23
Pathological grading of lymph node metastasis, pN (JES 10th)
Lymph node metastasis
Cases (%)
pN0
2335 (47.6%)
pN1
936 (19.1%)
pN2
1000 (20.4%)
pN3
354 (7.2%)
pN4
254 (5.2%)
Unknown
31 (0.6%)
Total
4910
Table 24
Pathological grading of lymph node metastasis, pN (UICC TNM 7th)
Lymph node metastasis
Cases (%)
pN0
2361 (48.1%)
pN1 (1–2)
1374 (28.0%)
pN2 (3–6)
757 (15.4%)
pN3 (7–)
366 (7.5%)
Unknown
52 (1.1%)
Total
4910
Table 25
Pathological findings of distant organ metastasis, pM (JES 10th)
Distant metastasis (M)
Cases (%)
MX
125 (2.5%)
M0
4715 (96.0%)
M1
70 (1.4%)
Total
4910
Table 26
Residual tumor
Residual tumor (R)
Cases (%)
RX
126 (2.6%)
R0
4359 (88.8%)
R1
239 (4.9%)
R2
186 (3.8%)
Total
4910
Table 27
Cause of death
Cause of death
Cases (%)
Death due to recurrence
1584 (63.8%)
Death due to other cancer
193 (7.8%)
Death due to other disease (with recurrence)
50 (2.0%)
Death due to other disease (without recurrence)
330 (13.3%)
Death due to other disease (recurrence unknown)
15 (0.6%)
Operative deatha
38 (1.5%)
Postoperative hospital deathb
59 (2.4%)
Unknown
213 (8.6%)
Total of death cases
2482
aOperative death means death within 30 days after operation in or out of hospital. Operative mortality rate: 0.77%
bHospital death is defined as death during the same hospitalization, regardless of department at time of death. Hospital mortality rate: 1.98%

Compliance with ethical standards

Conflict of interest

All authors have nothing to disclose with regard to commercial support.

Ethical statement

All procedures followed in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
insite
INHALT
download
DOWNLOAD
print
DRUCKEN

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt testen 1

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Jetzt testen 2
Literatur
1.
Japan Esophageal Society. Japanese classification of esophageal cancer, 10th edition: part 1. Esophagus. 2009;6:1–25.CrossRef
2.
Sobin LH, Gospodarowicz MK, Wittekind C, UICC International Union Against Cancer. TNM classification of malignant tumors. 7th ed. New York: Wiley-Blackwell; 2009.
Metadaten
Titel
Comprehensive registry of esophageal cancer in Japan, 2013
verfasst von
Masayuki Watanabe
Yuji Tachimori
Tsuneo Oyama
Yasushi Toh
Hisahiro Matsubara
Masaki Ueno
Koji Kono
Takashi Uno
Ryu Ishihara
Kei Muro
Hodaka Numasaki
Koji Tanaka
Soji Ozawa
Kentaro Murakami
Shiyori Usune
Arata Takahashi
Hiroaki Miyata
The Registration Committee for Esophageal Cancer of the Japan Esophageal Society
Publikationsdatum
13.10.2020
Verlag
Springer Singapore
Erschienen in
Esophagus / Ausgabe 1/2021
Print ISSN: 1612-9059
Elektronische ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-020-00785-y

Weitere Artikel der Ausgabe 1/2021

Esophagus 1/2021 Zur Ausgabe

Review Article

Multimodality approaches to control esophageal cancer: development of chemoradiotherapy, chemotherapy, and immunotherapy

Review Article

Review of clinical results of charged-particle therapy for esophageal cancer

Original Article

The treatment efficacy of adding prokinetics to PPIs for gastroesophageal reflux disease: a meta-analysis

Original Article

Relationship between gastroesophageal reflux disease (GERD) and constipation: laxative use is common in GERD patients

Original Article

Esophageal squamous cell carcinoma or high-grade dysplasia overlying leiomyoma, rare but not to be neglected

Original Article

Differences in clinical characteristics between conservative-treatment-response group and refractory (surgical-treatment) group in patients with jackhammer esophagus

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Metformin rückt in den Hintergrund

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise